166954-07-0

Basic information

• Product Name: Piperazine, 1-(2,6-dimethyl-4-pyridinyl)- (9CI)
• Synonyms: Piperazine, 1-(2,6-dimethyl-4-pyridinyl)- (9CI);1-(2,6-DIMETHYLPYRIDIN-4-YL)PIPERAZINE;1-(2,6-dimethylpyridin-4-yl)piperazine(SALTDATA: FREE)
• CAS NO: 166954-07-0
• Molecular Formula: C₁₁H₁₇N₃
• Molecular Weight: 191.27278
• Product Categories: PIPERIDINE
• Mol File: 166954-07-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 354.6°C at 760 mmHg
• Flash Point: 168.3°C
• Appearance: /
• Density: 1.042g/cm³
• Vapor Pressure: 3.31E-05mmHg at 25°C
• Refractive Index: 1.539
• PKA: 12.27±0.10(Predicted)
• CAS DataBase Reference: Piperazine, 1-(2,6-dimethyl-4-pyridinyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 1-(2,6-dimethyl-4-pyridinyl)- (9CI)(166954-07-0)
• EPA Substance Registry System: Piperazine, 1-(2,6-dimethyl-4-pyridinyl)- (9CI)(166954-07-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 166954-07-0(Hazardous Substances Data)

Usage

General Description

Piperazine, 1-(2,6-dimethyl-4-pyridinyl)- (9CI) is a chemical compound with the molecular formula C9H14N2. It is classified as a piperazine derivative and is characterized by the presence of a pyridine ring with two methyl substitutions. Piperazine, 1-(2,6-dimethyl-4-pyridinyl)- (9CI) may have various pharmaceutical and industrial applications, including use as an intermediate in the synthesis of pharmaceutical drugs, agrochemicals, and other specialty chemicals. It may also be used in research and development processes for the production of new chemical compounds with potential biological or industrial properties. Additionally, it is important to handle this compound with caution and in accordance with proper safety protocols and guidelines due to its potential hazards and toxicological properties.

InChI:InChI=1/C11H17N3/c1-9-7-11(8-10(2)13-9)14-5-3-12-4-6-14/h7-8,12H,3-6H2,1-2H3

Upstream product

• 5093-70-9 4-bromo-2,6-dimethylpyridine 

Relevant articles and documents

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.